atezolizumab + gemcitabine + carboplatin

Atezolizumab + gemcitabine + carboplatin is an investigational combination regimen that merges: - **Atezolizumab**, a monoclonal antibody targeting programmed death ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to stimulate antitumor immune responses; - **Gemcitabine**, a nucleoside analog and antimetabolite chemotherapeutic agent; - **Carboplatin**, a platinum-based chemotherapeutic agent causing DNA crosslinking and damage. This combination is under investigation for several advanced cancers, including triple-negative breast cancer (TNBC) and muscle-invasive bladder cancer, exploiting immunotherapy with atezolizumab and the cytotoxic effects of chemotherapy. The combination aims to leverage the synergistic effects of immune checkpoint inhibition and DNA-damaging chemotherapy, leading to improved clinical outcomes such as progression-free and overall survival in some cancer types[1][2][4].

Other names

atezolizumabgemcitabinecarboplatin